No Impact Expected from Change in Auditor at SciClone Pharma (SCLN); China Looks Better - Analyst (GSK)
Tweet Send to a Friend
Aegis Capital maintains its Buy rating and $8 price target on SciClone Pharmaceuticals (Nasdaq: SCLN) amid a recent change in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
